First-level protection from the infection is afforded by mucosal IgA antibodies; although the mRNA vaccine is not able to directly induce detectable salivary IgA antibodies, they may be produced by memory B-cells attracted to the inflammation site [123]. This evidence concerns the gene CD79A and infection.